Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis (Q34329513)

1 August 2017

0 references

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis (English)

1 reference

1 August 2017

1 reference

1 reference

1 reference

1 reference

Nicolas Flori

1

1 reference

1 August 2017

Natalie Funakoshi

2

1 reference

1 August 2017

Yohan Duny

3

1 reference

1 August 2017

Jean-Christophe Valats

4

1 reference

1 August 2017

Michael Bismuth

5

1 reference

1 August 2017

Dimitri Christophorou

6

1 reference

1 August 2017

Jean-Pierre Daurès

7

1 reference

1 August 2017

Pierre Blanc

8

1 reference

1 August 2017

publication date

1 March 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

73

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

263-277

1 reference

Diagnosis, management, and treatment of hepatitis C

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Treating hepatitis C in patients with cirrhosis: the effort is worth it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0027-1

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study

21 January 2018

1 reference

12 December 2020

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.

1 reference

12 December 2020

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

1 reference

12 December 2020

Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

1 reference

12 December 2020

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.

1 reference

12 December 2020

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

1 reference

12 December 2020

10.1007/S40265-013-0027-1

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1040724439

0 references

1 reference